Drug Profile
MVA 5T4
Alternative Names: 5T4 cancer vaccine; Cancer vaccine - Oxford Biomedica; Modified vaccinia Ankara 5T4; MVA-5T4; MVA-h 5T4; OBA 1 cancer vaccine; OXB-301; Recombinant modified vaccinia Ankara 5T4 vaccine; rV-5T4-VAC; SAR-109659; TroVaxLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Oxford BioMedica
- Developer Cardiff University; Oxford BioMedica; University College London; Wales Cancer Trials Unit
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Discontinued Colorectal cancer; Malignant-mesothelioma; Ovarian cancer; Prostate cancer; Renal cell carcinoma
Most Recent Events
- 19 Sep 2020 Efficacy data from the phase II TRIOC trial in Ovarian cancer presented at the 45th European Society for Medical Oncology Congress (ESMO-2020)
- 11 Jul 2019 Discontinued - Phase-II for Colorectal cancer (Inoperable/Unresectable, Metastatic disease) in United Kingdom (IM) (Oxford BioMedica pipeline - July 2019)
- 11 Jul 2019 Discontinued - Phase-II for Malignant mesothelioma (Combination therapy, First-line therapy) in United Kingdom (IM) (Oxford BioMedica pipeline - July 2019)